A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits.
The military population has a high disease burden of acute viral respiratory infections in China. To assess the efficacy and safety of a low-dose recombinant human interferon alpha-2b (rIFNalpha-2b) nasal spray in preventing acute viral respiratory infections in military population, we performed this randomized controlled trial. The results showed that application of the rIFNalpha-2b nasal spray had the benefits in prevention of infections caused by influenza A virus, influenza B virus parainfluenza viruses 1-3 and adenovirus species B. However, no benefit was seen in preventing respiratory syncytial virus. No severe adverse events were reported. Therefore, the rIFNalpha-2b nasal spray was effective and well tolerated for preventing common viral respiratory infections in the military recruits.
Gao
Lulu
L
Department of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, 1838 Guangzhou North Road, Guangzhou, 510515 Guangdong Province, China.
Yu
Shouyi
S
Chen
Qing
Q
Duan
Zhaojun
Z
Zhou
Jie
J
Mao
Chen
C
Yu
Dexian
D
Zhu
Wenchang
W
Nie
Jun
J
Hou
Yunde
Y
D000281:Administration, Intranasal; D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002681:China; D004311:Double-Blind Method; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008889:Military Personnel; D011994:Recombinant Proteins; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000821:virology; D014777:Virus Diseases / Q000188:drug therapy / Q000517:prevention & control*; D055815:Young Adult
D000914:Antibodies, Viral; D000998:Antiviral Agents; D007075:Immunoglobulin M; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Antiviral Res. 2002 Aug;55(2):227-78
12103428
Vaccine. 2002 Dec 20;20 Suppl 5:B36-9
12477417
Vaccine. 2005 Mar 14;23(16):1981-5
15734071
Emerg Infect Dis. 2006 Jan;12(1):29-33
16494713
J Clin Virol. 2008 Sep;43(1):120-2
18538629
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2003 Sep;17(3):205-8
15340558
J Clin Epidemiol. 2003 Dec;56(12):1218-23
14680673
Mil Med. 2005 Jan;170(1):94-7
15724862
Chest. 2003 Jan;123(1):209-16
12527624
Arch Dis Child. 1993 Oct;69(4):440-2
8259875
Antiviral Res. 1990 Jul;14(1):3-10
2080867
Vaccine. 2007 Oct 10;25(41):7017-30
17728025
J Infect Dis. 1986 Jul;154(1):128-33
3011917
J Infect Dis. 1984 Aug;150(2):181-8
6381611
Clin Infect Dis. 2002 Oct 1;35(7):808-18
12228817
J Infect Dis. 1986 Sep;154(3):443-7
3016111
Emerg Infect Dis. 2006 Jan;12(1):23-8
16494712
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):207-10
16261198
Antiviral Res. 2006 Jun;70(2):1-16
16513187
Vaccine. 2008 Jun 2;26(23):2890-8
18448211
J Med Virol. 1985 Oct;17(2):99-106
2997387
J Infect Dis. 1983 Nov;148(5):914-21
6355321
Med J Aust. 1990 May 21;152(10):524, 527-8
1692602
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Sep;19(3):211-5
16261199
J Infect Dis. 2004 Apr 1;189(7):1164-7
15031783